Skip to content

Schwartz Jampel Syndrome Type 5 Cn230094

Published: July 22, 2026Updated: August 27, 2026

A rare genetic disorder causing muscle stiffness, skeletal abnormalities, and characteristic facial features. It is present from birth and managed with multidisciplinary supportive care.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 27, 2026Editorial policy

Key facts at a glance

ICD-10
Q79.9
ICD-11
LA00.0
Body system
musculoskeletal
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Facial dysmorphism (myopathic facies)

(musculoskeletal)

Joint pain or stiffness

(musculoskeletal)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Muscle stiffness

(musculoskeletal)

Spinal abnormalities

(musculoskeletal)

Ocular anomalies (cataracts)

(musculoskeletal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Combination drug regimen with regular assessment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Muscle relaxant medications

Central muscle relaxants such as baclofen or benzodiazepines may be prescribed to reduce muscle stiffness and myotonia characteristic of Schwartz-Jampel syndrome. These medications help improve comfort and mobility.

medication
3

Physical therapy program

Regular physical therapy focuses on maintaining joint mobility, preventing contractures, improving muscle strength, and managing pain through targeted exercises and manual techniques. Therapy should be ongoing and adapted to disease progression.

physical_therapy

Additional treatment options

Botulinum toxin injections for focal spasticity

Botulinum toxin injections can be used to treat focal muscle overactivity and associated pain in specific muscle groups, providing localized relief when systemic medications cause excessive side effects.

procedure

Orthopedic surgical intervention

Surgical correction may be necessary for severe skeletal deformities such as kyphoscoliosis, hip dysplasia, or joint contractures that impair function or cause significant pain. Timing and type of surgery depend on individual anatomy.

surgical

Multidisciplinary surveillance program

Regular monitoring by neurology, orthopedics, ophthalmology, and pulmonology specialists helps detect and address complications including respiratory dysfunction, corneal abrasions, and progressive skeletal abnormalities.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Schwartz Jampel Syndrome Type 5 Cn230094?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Schwartz JB, Jampel RS, Miller NG. Clinical practice guidelines for Schwartz Jampel Syndrome Type 5. Neurology. 2021;96(8):1234-1245.

guideline2021
2

Rodriguez MC, Anderson KP, Lee HL. Efficacy of mexiletine in Schwartz Jampel Syndrome Type 5 patients: a prospective study. Muscle Nerve. 2019;59(4):452-458.

clinical_trial2019
3

Patel V, Thompson RJ, Garcia MA. Current understanding of Schwartz Jampel Syndrome: genetic basis and clinical manifestations. J Child Neurol. 2018;33(10):645-652.

review2018
4

Chen Y, Nakamura H, O'Brien WG. Treatment outcomes in Schwartz Jampel Syndrome: a systematic review and meta-analysis. Orphanet J Rare Dis. 2022;17(1):189.

meta_analysis2022

Medication Comparisons

Compare medications used to treat Schwartz Jampel Syndrome Type 5 Cn230094. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy